Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

32°
- Benton, AR (72018)
  Today
  
  Abundant sunshine. High around 60F. Winds light and variable..
  
  Tonight
  
  Clear skies. Low 36F. Winds light and variable.
  
  Updated: December 31, 2025 @ 8:22 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

7.915 +0.045 (+0.57%)

Streaming Delayed Price Updated: 9:49 AM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 Next >

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

November 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

November 10, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

October 07, 2025

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

August 14, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 09, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

February 21, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

January 22, 2025

MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary...

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 09, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

November 13, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

October 22, 2024

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

October 15, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

October 09, 2024

Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

August 12, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

August 12, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

May 09, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx to Participate in Upcoming Investor Conferences

April 24, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

April 18, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

March 14, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

February 13, 2024

MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of...

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

December 21, 2023

From MeiraGTx

Via GlobeNewswire

MeiraGTx to Participate in Upcoming Investor Conferences

November 21, 2023

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

November 14, 2023

From MeiraGTx

Via GlobeNewswire

BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions

October 31, 2023

Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a...

Via TheNewswire.com

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

October 30, 2023

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

October 24, 2023

Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

August 10, 2023

From MeiraGTx

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

Press Releases about MeiraGTx Holdings plc - Ordinary Shares

Sections

Services

Follow Us